Literature DB >> 1537890

Susceptibility to verotoxin as a function of the cell cycle.

A Pudymaitis1, C A Lingwood.   

Abstract

Infection with Verotoxin producing Escherichia coli (VTEC) has been implicated in hemolytic uremic syndrome, the leading cause of pediatric renal failure. Verotoxin (VT) binds to globotriaosylceramide (Gal alpha 1-4Gal beta 1-4GlcCer Gb3) in susceptible cells. Gb3 is required for cytotoxicity and toxin-resistant cells deficient in Gb3 can be sensitized to VT cytotoxicity by incorporation of exogenous Gb3 into the cells. However, the absolute Gb3 content of cell lines does not necessarily correspond directly with the degree of sensitivity to VT. The present study demonstrates that susceptibility to VT is a function of cell growth and that stationary phase cells are resistant to VT. Using chemically synchronized Vero cells, we have also found a tenfold difference in susceptibility to VT during the cell cycle. Our experiments define a maximal sensitivity "window" of 1-2 hours from the G1/S boundary. This corresponds to increased VT binding without change in overall Gb3 content. Cell surface labelling indicated that cyclic turnover and exposure of Gb3 may be the critical parameter in determining VT sensitivity. Such changes during the cell cycle may also be of relevance in vivo in determining toxin pathology during VTEC infections and the physiology of plasma membrane Gb3.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1537890     DOI: 10.1002/jcp.1041500324

Source DB:  PubMed          Journal:  J Cell Physiol        ISSN: 0021-9541            Impact factor:   6.384


  13 in total

1.  Verotoxins inhibit the growth of and induce apoptosis in human astrocytoma cells.

Authors:  S Arab; M Murakami; P Dirks; B Boyd; S L Hubbard; C A Lingwood; J T Rutka
Journal:  J Neurooncol       Date:  1998-11       Impact factor: 4.130

2.  Localization of potential binding sites for the edema disease verotoxin (VT2e) in pigs.

Authors:  T E Waddell; B L Coomber; C L Gyles
Journal:  Can J Vet Res       Date:  1998-04       Impact factor: 1.310

3.  Decreased incorporation of D-glucosamine into glycosphingolipids of intact Familial Dysautonomia lymphoblasts.

Authors:  P M Strasberg; A Novak; I B Warren
Journal:  J Mol Neurosci       Date:  1995       Impact factor: 3.444

Review 4.  Blood Groups in Infection and Host Susceptibility.

Authors:  Laura Cooling
Journal:  Clin Microbiol Rev       Date:  2015-07       Impact factor: 26.132

5.  Increased globotriaosylceramide on plasma membranes of synchronized familial dysautonomia cells. Verotoxin binding studies.

Authors:  J Pereira; B Boyd; J Newbigging; C Lingwood; P M Strasberg
Journal:  J Mol Neurosci       Date:  1994       Impact factor: 3.444

6.  Shiga toxin-associated hemolytic uremic syndrome: interleukin-1 beta enhancement of Shiga toxin cytotoxicity toward human vascular endothelial cells in vitro.

Authors:  S A Kaye; C B Louise; B Boyd; C A Lingwood; T G Obrig
Journal:  Infect Immun       Date:  1993-09       Impact factor: 3.441

7.  Cell density-induced changes in lipid composition and intracellular trafficking.

Authors:  Simona Kavaliauskiene; Carl-Martin Nymark; Jonas Bergan; Roger Simm; Tuulia Sylvänne; Helena Simolin; Kim Ekroos; Tore Skotland; Kirsten Sandvig
Journal:  Cell Mol Life Sci       Date:  2013-08-07       Impact factor: 9.261

8.  The bacterial colicin active against tumor cells in vitro and in vivo is verotoxin 1.

Authors:  H Farkas-Himsley; R Hill; B Rosen; S Arab; C A Lingwood
Journal:  Proc Natl Acad Sci U S A       Date:  1995-07-18       Impact factor: 11.205

9.  Alteration of the glycolipid binding specificity of the pig edema toxin from globotetraosyl to globotriaosyl ceramide alters in vivo tissue targetting and results in a verotoxin 1-like disease in pigs.

Authors:  B Boyd; G Tyrrell; M Maloney; C Gyles; J Brunton; C Lingwood
Journal:  J Exp Med       Date:  1993-06-01       Impact factor: 14.307

10.  Failure of manganese to protect from Shiga toxin.

Authors:  Marsha A Gaston; Christine A Pellino; Alison A Weiss
Journal:  PLoS One       Date:  2013-07-16       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.